NCNA NuCana plc IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1709626 · Reporting currency GBP · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: GBP | 2025Q2*2025-06-30 | 2024Q2*2024-06-30 | 2023Q2*2023-06-30 | 2022Q2*2022-06-30 | 2021Q4*2021-12-31 | 2021Q3*2021-09-30 | 2021Q2*2021-06-30 | 2021Q1*2021-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | 7.10M | 6.77M | 3.96M | 6.41M | 10.63M | 8.97M | 8.52M | 8.71M |
| Operating income | -11.83M | -8.35M | -6.28M | -5.22M | -15.74M | -9.97M | -10.71M | -11.49M |
| Interest expense | 12.65M | 0 | — | — | — | — | — | — |
| Pretax income | -24.44M | -8.27M | -6.10M | -5.09M | -15.71M | -9.95M | -10.67M | -11.46M |
| Income tax | -328,000 | -1.27M | -685,000 | -1.19M | -2.07M | -1.91M | -1.58M | -1.70M |
| Net income | -24.11M | -7.00M | -5.41M | -3.89M | -13.64M | -8.04M | -9.09M | -9.76M |
| EBITDA | — | — | — | — | -15.47M | -9.74M | -10.48M | -11.27M |
| EPS (basic) | 0.00 | -0.12 | -0.10 | -0.07 | — | -0.15 | -0.17 | -0.19 |
| EPS (diluted) | 0.00 | -0.12 | -0.10 | -0.07 | — | -0.15 | -0.17 | -0.19 |
| Balance sheet | ||||||||
| Cash & equivalents | 8.44M | 11.64M | 24.64M | 46.53M | 60.26M | 71.03M | 73.42M | 78.62M |
| Receivables | 1.02M | 2.04M | 2.62M | 3.93M | 4.16M | 5.13M | 4.20M | 4.81M |
| Current assets | 13.73M | 17.34M | 37.89M | 60.87M | 71.61M | 81.30M | 86.43M | 94.97M |
| PP&E, netmay include right-of-use assets (IFRS) | 178,000 | 343,000 | 701,000 | 613,000 | 851,000 | 952,000 | 1.04M | 1.10M |
| Intangibles | 2.20M | 2.21M | 2.55M | 2.47M | 2.41M | 4.90M | 4.81M | 4.76M |
| Total assets | 16.22M | 20.07M | 41.26M | 66.63M | 77.47M | 89.78M | 92.32M | 100.87M |
| Current liabilities | 8.70M | 16.06M | 13.54M | 10.43M | 11.72M | 12.10M | 7.86M | 9.07M |
| Total liabilities | 8.83M | 16.27M | 13.88M | 10.60M | 11.93M | 12.34M | 8.13M | 9.41M |
| Shareholders' equity | 7.38M | 3.80M | 27.38M | 56.03M | 65.55M | 77.45M | 84.19M | 91.46M |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | -10.09M | -805,000 | -4.86M | -8.07M |
| Capital expenditure | — | — | — | — | 21,000 | 6,000 | 33,000 | 4,000 |
| Free cash flow | — | — | — | — | -10.11M | -811,000 | -4.89M | -8.08M |
| Investing cash flow | — | — | — | — | -463,000 | -2.80M | -180,000 | -118,000 |
| Financing cash flow | — | — | — | — | -74,000 | -74,000 | -74,000 | 124,000 |
| Depreciation & amortization | — | — | — | — | 269,000 | 229,000 | 222,000 | 222,000 |
| Stock-based compensation | 8.00M | 700,000 | 1.10M | 1.20M | 1.75M | 1.30M | 1.80M | 1.79M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.